Quick Answer
Corbus Pharmaceuticals Holdings, Inc. reported R&D Expense of $70.09 million for fiscal year 2025.
Corbus Pharmaceuticals Holdings, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $70.09M | +117.5% |
| 2024 | $32.22M | +3.4% |
| 2023 | $31.17M | +93.1% |
| 2022 | $16.14M | -55.7% |
| 2021 | $36.45M | -62.9% |
| 2020 | $98.27M | +9.7% |
| 2019 | $89.60M | +84.3% |
| 2018 | $48.61M | +86.7% |
| 2017 | $26.04M | +68.7% |
| 2016 | $15.44M | +162.1% |
| 2015 | $5.89M | +369.0% |
| 2014 | $1.26M | +496.0% |
| 2013 | $210.7K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $20.86M | +93.0% | +37.4% |
| June 30, 2025 | $15.19M | +121.2% | -2.9% |
| March 31, 2025 | $15.64M | +171.5% | +44.7% |
| September 30, 2024 | $10.81M | +65.0% | +57.4% |
| June 30, 2024 | $6.87M | +61.6% | +19.1% |
| March 31, 2024 | $5.76M | -57.0% | -12.0% |
| September 30, 2023 | $6.55M | +59.5% | +54.2% |
| June 30, 2023 | $4.25M | +70.0% | -68.3% |
- Corbus Pharmaceuticals Holdings, Inc. showed an increase of +117.5% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2025 period, Corbus Pharmaceuticals Holdings, Inc.’s r&d expense has grown by 33172.4% (from $210.7 thousand to $70.09 million).
- The most recent figure is from Corbus Pharmaceuticals Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: